The company picked up de novo approval for the local treatment of breast cancer in patients ≥70 years of age with biologically low-risk tumors ≤1.5 cm in size and treated with adjuvant endocrine therapy. It says this represents approximately 46,000 women annually in the U.S. Clearance includes patients not suitable for surgery for breast cancer treatment.

IceCure designed ProSense as a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. It harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction. The system can help accelerate recovery, reduce pain, surgical risks and complications.